Industries > Pharma > Global Biomarkers Market Forecast 2017-2027

Global Biomarkers Market Forecast 2017-2027

Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

PUBLISHED: 18 October 2017
PAGES: 206
PRODUCT CODE: PHA0248

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 66 tables and 59 figures– all unavailable elsewhere.

The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biomarkers Market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global biomarkers market by Sector:
– Biomarker Services
– Biomarker Diagnostics
– Biomarker Discovery

• This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
– Genomics
– Proteomics
– Bioinformatics
– Other

• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
– Cancer
– Cardiovascular Diseases
– CNS,
– Autoimmune Diseases
– Other

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– EU5 (further segmented into France, Germany, the UK, Spain and Italy)
– Japan
– China
– India
– Russia
– Brazil
– RoW

Global Biomarkers Market Forecast 2017-2027

• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.

• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
– Quintiles IMS Holdings Inc
– Laboratory Corporation of America Holdings
– Parexel
– Charles River Laboratories
– ICON plc
– WuXi PharmaTec
– Caprion Proteomics
– Proteome Sciences
– Pacific Biomarkers
– Oxford Gene Technology (OGT)
– Worldwide Clinical Trials (WWC)
– Agilent
– AB SCIEX
– QIAGEN
– Axela Inc
– Thermo Fisher Scientific
– Quest Diagnostics
– Myriad Genetics
– Genomic Health
– Critical Diagnostics
– Epigenomics
– MDxHealth (formerly OncoMethylome)

• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
– Pfizer
– Novartis
– Roche Diagnostics
– Ventana Medical Systems
– Merck & Co.
– Sanofi
– GSK
– Abbott Laboratories
– AstraZeneca

Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Biomarkers: World Market Overview

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Market Definition, 2016


2. An Introduction to Biomarkers

2.1 Definition of a Biomarker

2.1.1 A Brief History of Biomarkers

2.1.2 The Importance of Biomarkers

2.2 Biomarker Discovery and Validation

2.3 Uses of Biomarkers

2.3.1 Assessing Drug Efficacy

2.3.2 Assessing Drug Safety

2.3.3 Companion Diagnostics

2.3.3.1 CLIA vs. FDA Approval

2.3.4 Therapeutic Importance of Biomarkers

2.3.5 Imaging Biomarkers

2.3.5.1 Imaging Biomarkers in Clinical Trials

2.4 Biomarkers and Personalised Medicine

2.5 Biomarker Discovery

2.5.1 Genomics

2.5.1.1 Pharmacogenomics

2.5.2 Proteomics

2.5.3 Metabolomics


3. The World Biomarkers Market, 2016-2027

3.1 The World Biomarkers Market, 2016

3.1.1 The World Biomarkers Market by Sector, 2016

3.1.2 The World Biomarkers Market by Discipline, 2016

3.2 The World Biomarkers Market: Overall Revenue Forecast, 2016-2027

3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market

3.3 The World Biomarker Discovery Submarket, 2016

3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2016-2027

3.4 The World Biomarker Diagnostics Submarket, 2016

3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2017-2027

3.5 The World Biomarker Services Submarket, 2016

3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2016-2027

3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2016-2027

3.6.1 The Genomics Submarket: Revenue Forecast, 2016-2027

3.6.1.1 Next Generation Sequencing to Drive Growth

3.6.1.2 Increased Focus on Genomic Research in China

3.6.1.3 Application in Cardiovascular Disease

3.6.2 The Proteomics Submarket: Revenue Forecast, 2016-2027

3.6.2.1 Advances in Detection Technology Will Drive Market

3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2016-2027

3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline

3.7 Growth in Key Biomarker Disciplines, 2016-2027


4. Leading Indications for Biomarker Discovery and Development, 2016-2027

4.1 The World Biomarkers Market by Indication, 2016

4.1.1 Class of biomarkers

4.1.2 Pharmacodynamic Biomarkers

4.2 The World Biomarkers Market: Overall Revenue Forecast by

Indication, 2016-2027

4.3 Cancer Biomarker Market

4.3.1 A Brief History of Cancer Biomarker Research

4.3.2 The Current State of Cancer Biomarker Research

4.3.3 Companion Diagnostics for Cancer

4.3.4 Initiatives in Cancer Biomarker Research

4.3.4.1 Cancer Genome Atlas

4.3.4.2 The Early Detection Research Network

4.3.5 Many Cancer Diagnostics Are Reaching the Market

4.3.6 Opportunities and Challenges for Cancer Biomarkers

4.3.6.1 Prostate Cancer: The Search for Urine Biomarkers

4.3.6.2 Lung Cancer: High Biomarker Owing to Disease Prevalence

4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2016-2027

4.4 Cardiovascular Disease Biomarker Submarket 2016

4.4.1 A Brief History of Cardiovascular Biomarker Research

4.4.2 The Current State of Cardiovascular Disease Biomarker Research

4.4.3 Cardiovascular Disease Diagnostics

4.4.3.1 Roche Troponin Test Approved by FDA

4.4.4 Collaborations in Cardiac Biomarker Research

4.4.4.1 Bayer Health Extends Collaboration with Broad Institute and Harvard

4.4.4.2 Singulex Inc Collaboration with University of Manchester

4.4.5 The Future of Cardiovascular Biomarker Research

4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2016-2027

4.5 CNS Diseases Biomarker Submarket, 2016

4.5.1 The Current State of CNS Disease Biomarker Research

4.5.2 Initiatives in CNS Disease Biomarker Research

4.5.3 Biomarker-Based Diagnostics for CNS Diseases

4.5.3.1 ADtect (DiaGenic)

4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare)

4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly)

4.5.3.4 Flutemetamol (GE Healthcare)

4.5.3.5 Florbetaben (Piramal Imaging)

4.5.4 CSF Biomarkers

4.5.5 Alzheimer’s Disease: Beyond Amyloid Beta

4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer’s Disease

4.5.6 Multiple Sclerosis: Search for Disease Biomarker

4.5.7 Parkinson’s Disease: Effective Biomarker Yet to be Discovered

4.5.7.1 Fluid-Based Biomarker Discovery

4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2016-2027

4.6 Autoimmune Disease Biomarker Submarket, 2016

4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease

4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease

4.6.2.1 Ventra DA – Myraid Genetics

4.6.2.2 NavigAID SSc – Protagen AG

4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer

4.6.3 Increasing consolidation within the market

4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders

4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics

4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2016-2027

4.7 Growth in Key Biomarker Indications, 2016-2027


5. Leading National Biomarker Markets, 2017-2027

5.1 The World Biomarkers Market: Regional Breakdown, 2016

5.2 The World Biomarkers Market: Regional Forecast, 2016-2027

5.3 US Biomarkers Market, 2016

5.3.1 FDA – New Draft Guidance on Companion Diagnostics

5.3.2 FDA major shift in regulation of laboratory developed tests

5.3.3 The US Biomarker Market: Revenue Forecast, 2016-2027

5.4 EU5 Biomarker Markets, 2016

5.4.1 EMA – New Draft Guidance on Companion Diagnostics

5.4.2 EMA – New Draft Guidance on Alzheimer’s Treatment

5.4.3 EU5 Biomarker Markets: Revenue Forecasts, 2016-2027

5.4.4 Germany Biomarker Market, 2016

5.4.4.1 Government initiatives: CancerMark Project

5.4.4.2 Germany: Biomarker Market Revenue Forecast, 2017-2027

5.4.5 France Biomarker Market, 2016

5.4.5.1 French Government Funds $17m Cancer Biomarker Effort

5.4.5.2 Immunid Received Funding for Companion Diagnostic for Skin Cancer

5.4.5.3 France: Biomarker Market Revenue Forecast, 2016-2027

5.4.6 UK Biomarker Market, 2016

5.4.6.1 Current stage of biomarker research in the UK

5.4.6.2 100,000 Genomes Project

5.4.6.3 £10 Million investment in Precision Panc project

5.4.6.4 The UK Biomarker Market: Revenue Forecast, 2017-2027

5.4.7 Spain Biomarker Market, 2016

5.4.7.1 Spain: Biomarker Market Revenue Forecast, 2016-2027

5.4.8 Italy Biomarker Market, 2016

5.4.8.1 Italian Government Initiatives on Genomics

5.4.8.2 Italy: Biomarker Market Revenue Forecast, 2017-2027

5.5 Japan Biomarker Market, 2016

5.5.1 PMDA – Guidance on Companion Diagnostics

5.5.2 Japan: Biomarker Market Revenue Forecast, 2017-2027

5.6 China Biomarker Market, 2016

5.6.1 Expanding Economy Driving Biotechnology in China

5.6.2 Companies Entering the Chinese Market

5.6.3 China: Biomarker Market Revenue Forecast, 2017-2027

5.7 India Biomarker Market, 2016

5.7.1 GenomeAsia 100K

5.7.2 New cancer institute funded by Indian Government

5.7.3 India: Biomarker Market Revenue Forecast, 2017-2027

5.8 Russia Biomarker Market, 2016

5.8.1 Russia: Biomarker Market Revenue Forecast, 2017-2027

5.9 Brazil Biomarker Market, 2016

5.9.1 Brazil: Biomarker Market Revenue Forecast, 2017-2027

5.10 RoW Biomarker Market, 2016


6. Biomarker Industry Trends, 2017-2027

6.1 Strengths and Weaknesses of the Biomarkers Market, 2016

6.2 Opportunities and Threats in the Biomarkers Market, 2017-2027

6.3 STEP Analysis of The World Biomarkers Market

6.4 Social Factors

6.4.1 Patient Stratification: Striving Towards Personalised Medicine

6.4.2 Biomarker Hype May Not Always Lead to New Discoveries

6.4.3 Growing Emphasis on Oncology for Companies

6.5 Technological Factors

6.5.1 Decreasing Size, Increasing Sensitivity

6.5.1.1 ABT Molecular Imaging

6.5.2 The Need for More-Efficient Data Storage

6.6 Economic Factors

6.6.1 Biomarkers: Cutting the Cost of Drug Development

6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures

6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups

6.6.3 Outsourcing Biomarker Discovery and Development

6.7 Political Factors

6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery

6.7.2 Improving Regulatory Guidelines to Speed Development

6.7.3 Concerns Over Biomarker Patenting Hits Innovation

6.8 Challenges in Developing Biomarkers

6.9 Combining Drug and Diagnostic Development

6.10 MicroRNA Biomarkers: A Prospective Target?

6.11 Big Pharma and Biomarkers

6.11.1 Pfizer

6.11.2 Novartis

6.11.3 Merck & Co.

6.11.4 Sanofi

6.11.5 Roche

6.11.5.1 Roche Diagnostics

6.11.5.2 Ventana Medical Systems

6.11.6 GSK

6.11.7 AstraZeneca

6.11.8 Abbott Laboratories


7. Leading Companies in the Biomarkers Market, 2016

7.1 Biomarker Service Providers

7.1.1 Global CROs and Biomarkers

7.1.1.1 Not All Global CROs Are Investing in Biomarkers

7.1.2 Quintiles IMS Holdings Inc

7.1.2.1 Quintiles and IMS Health Merger

7.1.3 Laboratory Corporation of America Holdings

7.1.3.1 LabCorp Diagnostics

7.1.3.2 Covance Drug development

7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2016

7.1.4 Parexel

7.1.5 Charles River Laboratories

7.1.6 ICON plc

7.1.7 WuXi PharmaTec

7.1.8 Caprion Proteomics

7.1.9 Proteome Sciences

7.1.10 Pacific Biomarkers

7.1.11 Oxford Gene Technology

7.1.12 Worldwide Clinical Trials

7.2 Biomarker Technology Providers

7.2.1 Agilent

7.2.1.1 Diagnostics and Biomarker Assays

7.2.1.2 Growing Asian Markets: Focus on South Korea

7.2.2 AB SCIEX

7.2.2.1 Partnership with Illumina, OneOmics project

7.2.3 QIAGEN

7.2.4 Axela

7.2.5 Thermo Fisher Scientific

7.2.5.1 Strategic Acquisitions

7.2.5.2 Research Collaborations

7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre

7.3 Biomarker Diagnostic Developers

7.3.1 Quest Diagnostics

7.3.1.1 Acquisition of Med Fusion and ClearPoint Diagnostics

7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc

7.3.2 Myriad Genetics

7.3.2.1 Pipeline

7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic

7.3.2.3 Strategic Acquisitions

7.3.2.4 Myriad RBM

7.3.3 Genomic Health

7.3.3.1 Collaborations with Epic Sciences and Biocartis

7.3.4 Critical Diagnostics

7.3.5 Epigenomics

7.3.5.1 Diagnostic Product Portfolio

7.3.6 MDxHealth

7.3.6.1 Diagnostic Product Portfolio and Pipeline


8. Conclusions

8.1 State of the World Biomarkers Market in 2016

8.2 Growth in the World Biomarkers Market, 2017-2027

8.2.1 Dominance of Leading Western Markets

8.3 The Use of Biomarkers in Drug Discovery and Development

8.4 Demand for New Diagnostics


Appendices

Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form


List of Figures

Figure 2.1 Definitions of a Biomarker, 2016

Figure 2.2 The Biomarker Discovery and Validation Process, 2016

Figure 3.1 World Biomarkers Market: Market Shares (%) by Sector, 2016

Figure 3.2 World Biomarkers Market: Market Shares (%) by Discipline, 2016

Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2016-2027

Figure 3.4 World Biomarkers Market: Overall Market Forecast ($bn), 2016-2027

Figure 3.5 World Biomarkers Market: Market Shares (%) by Sector, 2021

Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2027

Figure 3.7 Biomarker Discovery Submarket: Drivers and Restraints, 2017-2027

Figure 3.8 Biomarker Discovery Submarket: Revenue Forecast ($bn), 2016-2027

Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast ($bn), 2017-2027

Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2017-2027

Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2016-2027

Figure 3.12 Biomarker Services Submarket: Revenue Forecast ($bn), 2016-2027

Figure 3.13 Genomics Submarket: Revenue Forecast ($bn), 2016-2027

Figure 3.14 Genomics Submarket: Drivers and Restraints, 2016-2027

Figure 3.15 Proteomics Submarket: Drivers and Restraints, 2017-2027

Figure 3.16 Proteomics Submarket: Revenue Forecast ($bn), 2016-2027

Figure 3.17 Bioinformatics Submarket: Revenue Forecast ($bn), 2016-2027

Figure 3.18 Bioinformatics Submarket: Drivers and Restraints, 2016-2027

Figure 3.19 World Biomarkers Market: Market Shares (%) by Discipline, 2021

Figure 3.20 World Biomarkers Market: Market Shares (%) by Discipline, 2027

Figure 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016

Figure 4.2 Pharmacodynamic Biomarkers in Drug Labelling by Indication

Figure 4.3 Cancer Submarket: Revenue Forecast ($bn), 2016-2027

Figure 4.4 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2016-2027

Figure 4.5 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027

Figure 4.6 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027

Figure 4.7 World Biomarkers Market: Market Share (%) by Indication, 2021

Figure 4.8 World Biomarkers Market: Market Shares (%) by Indication, 2027

Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2016

Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2021

Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2027

Figure 5.4 US Biomarkers Market: Revenue Forecast ($bn), 2017-2027

Figure 5.5 Top 5 EU Biomarker Markets: Market Share (%) by Country, 2016

Figure 5.6 Top Five EU Biomarker Markets: Revenue Forecasts ($bn), 2017-2027

Figure 5.7 Germany: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.8 France: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.9 UK Biomarker Market: Revenue Forecast ($bn), 2017-2027

Figure 5.10 Spain: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.11 Italy: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.12 Japan Biomarker Market: Revenue Forecast ($bn), 2017-2027

Figure 5.13 China: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.14 India: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.15 Russia: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.16 Brazil: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 5.17 RoW: Biomarker Market Revenue Forecast ($bn), 2017-2027

Figure 6.1 US Cancer Deaths by Tumour Type, 2016

Figure 6.2 Average Cost of Sequencing the Human Genome ($mn), 2005-2015

Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2015-2016

Figure 7.2 Proteome Sciences: Revenue ($mn), 2015-2016

Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2016

Figure 7.4 Genomic Health: Product Revenue ($mn), 2015-2016

Figure 7.5 Epigenomics Revenue ($mn), 2016-2017

Figure 7.6 MDxHealth: Revenue by Source ($mn), 2015-2016

Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2016, 2021 and 2027

Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027

Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease, 2016, 2021 and 2027

Figure 8.4 World Biomarkers Market: Revenues ($bn) by Country, 2016, 2021 and 2027


List of Tables

Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2016

Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016

Table 2.3 Technologies and Platforms for Biomarker Research, 2016

Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2016

Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2016

Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2016-2027

Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2016, 2021, 2027

Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2016-2027

Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2016

Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2016, 2021, 2027

Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016

Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2016-2027

Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2016

Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2016

Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 4.7 Research Collaborations in CNS Biomarker Research

Table 4.8 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 4.9 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027

Table 4.10 World Biomarkers Market: Market Share (%) by Indication, 2016, 2021, 2027

Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2016

Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027

Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2016, 2021, 2027

Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2016

Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027

Table 5.7 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.8 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 5.17 RoW: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027

Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2017-2027

Table 6.2 World Biomarkers Market: Opportunities and Threats, 2017-2027

Table 6.3 World Biomarkers Market: STEP Analysis, 2017-2027

Table 6.4 US Cancer Deaths by Tumour Type, 2016

Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2016

Table 6.6 PSTC Biomarkers in Development, 2016

Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015

Table 6.8 IMI-Funded Biomarker Projects

Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2016, 2021 & 2027

Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2015-2016

Table 7.2 Proteome Sciences: Revenue ($mn), 2015-2016

Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2016

Table 7.4 Company Revenue by Sector ($mn), 2016

Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2016

Table 7.6 Genomic Health: Revenue by Division ($bn), 2015-2016

Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2015 -2016

Table 7.8 MDx Health: Revenue by Source ($mn), 2015-2016

Table 7.9 MDxHealth: Pipeline, 2016

Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2016, 2021 and 2027

Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2016, 2021 and 2027

Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2016, 20121 and 2027

Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2016, 2021 and 2027

454 Life Sciences (a subsidiary of Roche)

AB SCIEX

Abbott Laboratories

Abbott Molecular

Abcodia

ABT Molecular Imaging

ACS Biomarker

Advanced Cell Diagnostics (ACD)

Advion Bioanalytical Labs (part of Quintiles)

Affymetrix

Agendia

Agilent

Alacris Theranostics

Alere

Amarantus BioSciences

Amgen

Applied Biosystems (part of Life Technologies)

Aptiv Solutions

Arctic Partners

ARIAD Pharmaceuticals

Ariana Pharma

Arizona State University

Arrayit

ARUP Laboratories

AstraZeneca

Athena Diagnostics (a subsidiary of Quest Diagnostics)

Atherotech Diagnostics Lab

Aushon Biosystems

Axela Inc

Bayer

Belfer Institute for Applied Cancer Science [US]

Berkeley HeartLab (a subsidiary of Quest Diagnostics)

BG Medicine

BGI (formerly Beijing Genomics Institute)

Biofortis

Biosoft

BRAHMS (part of Thermo Fisher Scientific)

Brigham and Women’s Hospital

Bristol-Myers Squibb

Cancer Research Technology

Caprion Proteomics

CBC (Comprehensive Biomarker Centre GmbH)

Celera (part of Quest Diagnostics)

Celgene

Cell Signaling Technology

Celldex Therapeutics

Cephalon (part of Teva)

Charles River Laboratories

Chronix Biomedical

Chugai Pharmaceutical

Ciphergen Biosystems

Clarient Diagnostic Services

Cleveland HeartLab

Clinigene International

Comprehensive Biomarker Center (formerly Febit)

Covance

Crelux

Critical Diagnostics

Critical Path Institute (C-Path) [US]

CTI Biotech

Daiichi Sankyo

Dako (now part of Agilent)

Dana-Farber Cancer Institute [US]

Danaher

DaVita Labs

DiaGenic

Durin Technologies

DxS (now part of QIAGEN)

EKO Diagnostic

Eli Lilly and Co.

Epic Sciences

Epigenomics

Epistem

EQT

Evotec

Exact Sciences

Exiqon

Exonhit

Ezose Sciences (part of Shionogi)

FEI Company

Foundation Medicine

Fujirebio Diagnostics

GE Healthcare

Genetic Technologies

Geneva Bioinformatics (GeneBio)

Genomic Health

GenWay Biotech

Great Point Partners

GSK

HD Biosciences

Health Diagnostic Laboratory

HealthLinx

Helicos BioSciences

Hewlett-Packard

HTG Molecular Diagnostics

ICON Plc

Illumina

ImmunId

Insight Genetics

Institute of Pathology Heidelberg (IPH)

Integrated Diagnostics

Ipsen

Ipsogen (a subsidiary of QIAGEN)

Isogen Life Science

Johnson & Johnson (J&J)

KU Leuven (University of Leuven)

LabCorp

Life Technologies

LightArray Biotech

M2Gen

Mayo Clinic [US]

Mayo Collaborative Services

MDxHealth

Medical Research Council [UK]

MediMedia Pharma Solutions

Memorial Sloan-Kettering Cancer Center [US]

Merck & Co.

Merck KGaA

Metabolon

Michael J Fox Foundation

Myriad Genetics

Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)

National Academy of Sciences (NAS) [US]

Nephromics

Novartis

Novartis Molecular Diagnostics (part of Novartis)

NovioGendix

Oncoimmune

Oncomedics

OpGen

OPKO Health

Orion Genomics

Oxford Cancer Biomarkers

Oxford Gene Technology

Pacific Biomarkers

Pacific Biosciences

Panomics (now part of Affymetrix)

Parexel

Patheon

Pathwork Diagnostics

Personal Genome Diagnostics

Pfizer

Pierre Fabre

PLUS Diagnostics

PMDA

Power3 Medical Products

PPD

Predictive Biosciences

Prometheus Laboratories

ProtagenAG

Proteome Sciences

QIAGEN

QLIDA Diagnostics

Quanterix

Quanticel Pharmaceuticals

Quest Diagnostics

Quintiles

Quintiles IMS Holdings Inc

Randox Laboratories

Randox Laboratories

Roche

SABiosciences (now part of QIAGEN)

Sandor Proteomic

Sanger Institute

Sanofi

Santaris Pharma

Servier

Shionogi

Siemens

Siemens Healthcare

Singulex Inc

Sividion Diagnostics

SMA Foundation [US]

Stemina Biomarker Discovery

Sysmex

Technology Strategy Board (TSB) [UK]

Teva Pharmaceutical Industries

Thallion Pharmaceuticals

The Biomarkers Consortium

Thermo Fisher Sciences

Thermo Fisher Scientific

Transgene

Trans-Hit Biomarkers

Tufts Center for the Study of Drug Development

Ventana Medical Systems

Vertex Pharmaceuticals

WaferGen

Warnex

Worldwide Clinical Trials

WuXi AppTec

Wuxi Pharmatech

Xcovery


List of Organizations Mentioned in the Report

American College of Cardiology Foundation (ACCF)

American Heart Association (AHA)

Association for Molecular Pathology (AMP) [US]

British Heart Foundation [UK]

Broad Institute [US]

Cancer Research UK

Centers for Medicare and Medicaid Services (CMS) [US]

Chinese State Food and Drug Administration (SFDA)

Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]

EMA (European Medicines Agency)

ETH Zurich

European Commission

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Medicines Agency (EMA)

European Stroke Research Network for Hypothermia (Euro-HYP)

Food and Drug Administration (FDA) [US]

Hirosaki University

Human Proteome Organisation (HUPO)

International Cancer Genome Consortium (ICGC)

Les entreprises du médicament (LEEM) [France]

Malmö University

Massachusetts General Hospital

Max Planck Institute for Molecular Genetics [Germany]

National Academy of Sciences

National Cancer Institute (NCI) [US]

National Health Service (NHS) [UK]

National Human Genome Research Institute (NHGRI) [US]

National Institute for Health and Clinical Excellence (NICE) [UK]

National Institute of Allergy and Infectious Diseases (NIAID) [US]

National Institute on Aging (NIA) [US]

National Jewish Health [US]

Newcastle University [UK]

NIH (National Institute of Health)

Oslo University Hospital

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

Predictive Safety Testing Consortium (PSTC) [US]

Shanghai Jiao Tong University

Stanford University

State Food and Drug Administration (SFDA) [China]

Technion-Israel Institute of Technology

University of Alabama

University of Medicine and Dentistry of New Jersey (UMDNJ)

University of Oslo

University of Turku

University of Washington

Wellcome Trust Sanger Institute [UK]

World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Global Biomarkers Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Biomarkers Market Forecast 2017-2027


Do you have any custom requirements we can help you with?

Any specific country, geo region, market segment or specific company information?

Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“Biobanking market set to grow to $4.2bn by 2024” says new Visiongain report

Biobanking infrastructure is improving at a global level with the establishment of large-scale national biobanks, population biobank projects, virtual biobanks and networking at national and international level.

23 May 2019

READ

“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs.

21 May 2019

READ

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

READ

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

READ

Categories

Category